Profile: Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

637.55INR
5:26am EST
Price Change (% chg)

Rs8.60 (+1.37%)
Prev Close
Rs628.95
Open
Rs630.00
Day's High
Rs642.00
Day's Low
Rs626.30
Volume
2,119,129
Avg. Vol
2,163,394
52-wk High
Rs673.00
52-wk Low
Rs366.50

Search Stocks
Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin acetate injection) for new antifungal for life-threatening fungal infections; Endobloc (ambrisentan tablets); Esomac (esomeprazole tablets); Evocort (formoterol and mometasone rotacaps)-new once-daily asthma controller therapy; Isablac (lactulose and isphaghula husk granules), and Ivabeat (ivabradine tablets) drug for coronary artery disease and chronic heart failure. In July 2013, the Company acquired Cipla Medpro South Africa Limited. In November 2013, the Company’s wholly owned step down subsidiary Meditab Holdings Limited, acquired an additional 14.5% interest in Quality Chemical Industries Limited (QCIL) and now held 51.05% interest in QCIL.

Company Address

Cipla Ltd

Mumbai Central
MUMBAI     400008
P: +9122.23082891
F: +9122.23070013

Search Stocks